198 related articles for article (PubMed ID: 35614270)
1. Predictive value of p53, Ki67 and TLR5 in neoplastic progression of Barrett's esophagus: a matched case-control study.
Helminen O; Melkko J; Saarnio J; Sihvo E; Kuopio T; Ohtonen P; Kauppila JH; Karttunen TJ; Huhta H
Virchows Arch; 2022 Sep; 481(3):467-476. PubMed ID: 35614270
[TBL] [Abstract][Full Text] [Related]
2. Aneuploidy and overexpression of Ki67 and p53 as markers for neoplastic progression in Barrett's esophagus: a case-control study.
Sikkema M; Kerkhof M; Steyerberg EW; Kusters JG; van Strien PM; Looman CW; van Dekken H; Siersema PD; Kuipers EJ
Am J Gastroenterol; 2009 Nov; 104(11):2673-80. PubMed ID: 19638963
[TBL] [Abstract][Full Text] [Related]
3. Malignant degeneration of Barrett's esophagus: the role of the Ki-67 proliferation fraction, expression of E-cadherin and p53.
Feith M; Stein HJ; Mueller J; Siewert JR
Dis Esophagus; 2004; 17(4):322-7. PubMed ID: 15569371
[TBL] [Abstract][Full Text] [Related]
4. Activation of Wnt signalling promotes development of dysplasia in Barrett's oesophagus.
Moyes LH; McEwan H; Radulescu S; Pawlikowski J; Lamm CG; Nixon C; Sansom OJ; Going JJ; Fullarton GM; Adams PD
J Pathol; 2012 Sep; 228(1):99-112. PubMed ID: 22653845
[TBL] [Abstract][Full Text] [Related]
5. Risk of progression in Barrett's esophagus based on diagnoses of general and gastrointestinal pathologists. A retrospective case-control study from Northern and Central Finland.
Huhta H; Melkko J; Kuopio T; Karttunen TJ; Helminen O
Scand J Gastroenterol; 2022 Sep; 57(9):1024-1029. PubMed ID: 35450519
[TBL] [Abstract][Full Text] [Related]
6. Surveillance in Barrett's esophagus: an audit of practice.
Ajumobi A; Bahjri K; Jackson C; Griffin R
Dig Dis Sci; 2010 Jun; 55(6):1615-21. PubMed ID: 19669878
[TBL] [Abstract][Full Text] [Related]
7. Apoptosis and cell proliferation in the metaplasia-dysplasia-carcinoma-sequence of Barrett's esophagus.
Halm U; Tannapfel A; Breitung B; Breidert M; Wittekind CW; Mössner J
Hepatogastroenterology; 2000; 47(34):962-6. PubMed ID: 11020858
[TBL] [Abstract][Full Text] [Related]
8. Origin of adenocarcinoma in Barrett's esophagus: p53 and Ki67 expression and histopathologic background.
Szachnowicz S; Cecconello I; Iriya K; Marson AG; Takeda FR; Gama-Rodrigues JJ
Clinics (Sao Paulo); 2005 Apr; 60(2):103-12. PubMed ID: 15880245
[TBL] [Abstract][Full Text] [Related]
9. Nuclear localization of Toll-like receptor 5 in Barrett's esophagus and esophageal adenocarcinoma is associated with metastatic behavior.
Helminen O; Huhta H; Leppänen J; Kauppila JH; Takala H; Lehenkari PP; Saarnio J; Karttunen TJ
Virchows Arch; 2016 Oct; 469(4):465-70. PubMed ID: 27392931
[TBL] [Abstract][Full Text] [Related]
10. The value of p53 and Ki67 as markers for tumour progression in the Barrett's dysplasia-carcinoma sequence.
Polkowski W; van Lanschot JJ; Ten Kate FJ; Baak JP; Tytgat GN; Obertop H; Voorn WJ; Offerhaus GJ
Surg Oncol; 1995 Jun; 4(3):163-71. PubMed ID: 7582189
[TBL] [Abstract][Full Text] [Related]
11. p53 protein accumulation in Barrett's metaplasia, dysplasia, and carcinoma: a follow-up study.
Younes M; Lebovitz RM; Lechago LV; Lechago J
Gastroenterology; 1993 Dec; 105(6):1637-42. PubMed ID: 8253340
[TBL] [Abstract][Full Text] [Related]
12. Aberrant p53 protein expression is associated with an increased risk of neoplastic progression in patients with Barrett's oesophagus.
Kastelein F; Biermann K; Steyerberg EW; Verheij J; Kalisvaart M; Looijenga LH; Stoop HA; Walter L; Kuipers EJ; Spaander MC; Bruno MJ;
Gut; 2013 Dec; 62(12):1676-83. PubMed ID: 23256952
[TBL] [Abstract][Full Text] [Related]
13. Analysis of Ki-67, p53 and Bcl-2 expression in the dysplasia-carcinoma sequence of Barrett's esophagus.
Rioux-Leclercq N; Turlin B; Sutherland F; Heresbach N; Launois B; Campion JP; Ramee MP
Oncol Rep; 1999; 6(4):877-82. PubMed ID: 10373674
[TBL] [Abstract][Full Text] [Related]
14. Expression of p53, PCNA, and C-erbB-2 in Barrett's metaplasia and adenocarcinoma.
Kim R; Clarke MR; Melhem MF; Young MA; Vanbibber MM; Safatle-Ribeiro AV; Ribeiro U; Reynolds JC
Dig Dis Sci; 1997 Dec; 42(12):2453-62. PubMed ID: 9440619
[TBL] [Abstract][Full Text] [Related]
15. p53 gene mutation and protein accumulation during neoplastic progression in Barrett's esophagus.
Bian YS; Osterheld MC; Bosman FT; Benhattar J; Fontolliet C
Mod Pathol; 2001 May; 14(5):397-403. PubMed ID: 11353048
[TBL] [Abstract][Full Text] [Related]
16. The diagnosis and management of Barrett's esophagus.
DeMeester SR; DeMeester TR
Adv Surg; 1999; 33():29-68. PubMed ID: 10572561
[TBL] [Abstract][Full Text] [Related]
17. Use of a Cytosponge biomarker panel to prioritise endoscopic Barrett's oesophagus surveillance: a cross-sectional study followed by a real-world prospective pilot.
Pilonis ND; Killcoyne S; Tan WK; O'Donovan M; Malhotra S; Tripathi M; Miremadi A; Debiram-Beecham I; Evans T; Phillips R; Morris DL; Vickery C; Harrison J; di Pietro M; Ortiz-Fernandez-Sordo J; Haidry R; Kerridge A; Sasieni PD; Fitzgerald RC
Lancet Oncol; 2022 Feb; 23(2):270-278. PubMed ID: 35030332
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of p53 protein expression in Barrett's esophagus by two-parameter flow cytometry.
Ramel S; Reid BJ; Sanchez CA; Blount PL; Levine DS; Neshat K; Haggitt RC; Dean PJ; Thor K; Rabinovitch PS
Gastroenterology; 1992 Apr; 102(4 Pt 1):1220-8. PubMed ID: 1551529
[TBL] [Abstract][Full Text] [Related]
19. Anti-phosphorylated histone H3 expression in Barrett's esophagus, low-grade dysplasia, high-grade dysplasia, and adenocarcinoma.
Goodarzi M; Correa AM; Ajani JA; Swisher SG; Hofstetter WL; Guha S; Deavers MT; Rashid A; Maru DM
Mod Pathol; 2009 Dec; 22(12):1612-21. PubMed ID: 19734842
[TBL] [Abstract][Full Text] [Related]
20. p53 immunoreactivity in Barrett's metaplasia, dysplasia, and carcinoma.
Rice TW; Goldblum JR; Falk GW; Tubbs RR; Kirby TJ; Casey G
J Thorac Cardiovasc Surg; 1994 Dec; 108(6):1132-7. PubMed ID: 7983883
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]